Want to see VKTX full AI Analyst Report?
VKTX Stock Chart & Stats
$34.79
-$0.60(-1.70%)
At close: 4:00 PM EDT
$34.79
-$0.60(-1.70%)
Day’s Range― - ―
52-Week Range$22.96 - $43.15
Previous CloseN/A
Volume1.84M
Average Volume (3M)2.52M
Market Cap
$3.70B
Enterprise Value$4.04K
Total Cash (Recent Filing)$501.66M
Total Debt (Recent Filing)$4.09M
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Oct 28, 2026EPS Estimate
-1.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.66
Shares Outstanding116,652,940
10 Day Avg. Volume1,815,615
30 Day Avg. Volume2,521,002
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)6.20
Price to Sales (P/S)0.00
P/FCF Ratio-14.22
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-0.02
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$92.08Price Target Upside164.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering14
EPS Forecast (FY)-4.75
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase III Programs Fully EnrolledLarge, fully enrolled Phase III trials materially reduce execution and statistical risk versus early‑stage studies. Robust enrollment demonstrates operational capability, strengthens the regulatory dataset probability, and supports a clearer path to potential approval and commercialization over the next 2–3 years.
Strong Phase II Efficacy For VK2735Clinically meaningful weight‑loss signals across subcutaneous and oral formulations indicate the program can be competitive versus existing therapies. Durable efficacy in Phase II supports higher likelihood of pivotal success, better commercial positioning, and potential label differentiation if replicated in Phase III.
Balance Sheet Strength And RunwayA multi‑year cash runway and extremely low leverage give the company time to complete pivotal trials without immediate refinancing. This financial flexibility preserves strategic optionality for trial completion, manufacturing scale decisions, and initial commercial build‑out planning over the medium term.
Bears Say
Accelerating Cash Burn And Widening LossesSustained and accelerating cash outflows materially raise funding and dilution risk. Even with runway into 2028, persistent negative FCF and steep losses imply the company will likely need additional capital if timelines slip or spend remains elevated, pressuring shareholder dilution and strategic flexibility.
Pre‑revenue Business ModelWithout commercial revenues, Viking depends on clinical success and capital markets to fund operations. This structural reliance amplifies binary risk: failed or delayed readouts force near‑term financing or program cuts, while successful outcomes are required to transition to sustainable revenue generation.
Clinical And Operational Execution RisksPotential off‑trial GLP‑1 use and unusual placebo effects can confound pivotal readouts, while a compressed maintenance titration raises tolerability uncertainty versus competitors. Early‑stage VK3019 adds pipeline optionality but is unproven, increasing overall clinical execution and regulatory risk.
Viking Therapeutics News
VKTX FAQ
What was Viking Therapeutics’s price range in the past 12 months?
Viking Therapeutics lowest stock price was $22.96 and its highest was $43.15 in the past 12 months.
What is Viking Therapeutics’s market cap?
Viking Therapeutics’s market cap is $3.70B.
When is Viking Therapeutics’s upcoming earnings report date?
Viking Therapeutics’s upcoming earnings report date is Oct 28, 2026 which is in 86 days.
How were Viking Therapeutics’s earnings last quarter?
Viking Therapeutics released its earnings results on Jul 29, 2026. The company reported -$1.1 earnings per share for the quarter, beating the consensus estimate of -$1.233 by $0.133.
Is Viking Therapeutics overvalued?
According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued.
Does Viking Therapeutics pay dividends?
Viking Therapeutics does not currently pay dividends.
What is Viking Therapeutics’s EPS estimate?
Viking Therapeutics’s EPS estimate is -1.07.
How many shares outstanding does Viking Therapeutics have?
Viking Therapeutics has 116,652,940 shares outstanding.
What happened to Viking Therapeutics’s price movement after its last earnings report?
Viking Therapeutics reported an EPS of -$1.1 in its last earnings report, beating expectations of -$1.233. Following the earnings report the stock price went down -0.957%.
Which hedge fund is a major shareholder of Viking Therapeutics?
Currently, no hedge funds are holding shares in VKTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Viking Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$92.08 (164.68% Upside)
$92.08 (164.68% Upside)
Blogger Sentiment
Bullish
VKTX Sentiment 81%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 86.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.3M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 0.2%
Last 30 Days ▼ 0.2%
News Sentiment
Very Bullish
Bullish news 93%
Bearish news 7%
Bearish news 7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.85%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-36.96%
Trailing 12-Months
Company Description
Viking Therapeutics
Viking Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation of novel treatments for metabolic and endocrine conditions. The company's leading investigational drug, VK2809, is an orally administered, tissue and receptor-selective agonist of the thyroid hormone receptor beta (TRß). This compound is currently progressing through Phase IIb clinical trials, targeting both non-alcoholic steatohepatitis (NASH) in biopsy-confirmed patients and non-alcoholic fatty liver disease (NAFLD). Viking's pipeline also features VK5211, an oral, non-steroidal selective androgen receptor modulator undergoing Phase II studies for individuals recuperating from non-elective hip fracture surgery. Additionally, VK0612, an oral drug candidate for type 2 diabetes, is poised to enter Phase IIb trials. The firm is also developing VK0214, another orally active, tissue and receptor-selective TRß agonist, specifically aimed at X-linked adrenoleukodystrophy. Founded in 2012, Viking Therapeutics is headquartered in San Diego, California.
VKTX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call highlights substantial clinical progress: fully enrolled large Phase III programs for subcutaneous VK2735, positive Phase II efficacy for both subcutaneous and oral formulations (notably up to 14.7% and 12.2% mean weight loss, respectively), initiation of an early-stage amylin/calcitonin program (VK3019), and organizational hires to support commercialization. These scientific and pipeline milestones are balanced against materially higher R&D spend, widening net losses and a meaningful cash decline (~28.9% year-to-date). Management reiterated cash runway into 2028 and expects cash burn to taper, while noting upcoming maintenance study data and oral Phase III initiation later in the year. Overall, clinical momentum and promising efficacy data are dominant positives, while financial burn and early-stage uncertainties are notable negatives.View all VKTX earnings summariesVKTX Stock 12 Month Forecast
Average Price Target
$92.08
▲(164.68% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Xenon
―
Scholar Rock Holding
―
Immunovant
―
NewAmsterdam Pharma Company
―
Ownership Overview
2.96% Insiders
18.23% Mutual Funds
1.33% Other Institutional Investors
63.64% Public Companies and Individual Investors